Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLARITY-PanTumour01
2023-508275-37-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Nov 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 2, randomised, open-label trial of sonesitatug vedotin in gastric cancer (GC), esophagogastric junction cancer, pancreatic adenocarcinoma (PDAC) and 1 more (7 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability and Objective response rate. Planned start Nov 2024; status: authorised.
02
Drugs
sonesitatug vedotin
03
Conditions
gastric cancer (GC)esophagogastric junction cancerpancreatic adenocarcinoma (PDAC)biliary cancer
Beyond the preview
Go deeper on 2023-508275-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508275-37-00.